Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine (EUREkA)

Vall d'Hebron University Hospital (HUVH)

Status

Enrolling

Conditions

Chronic Migraine, Headache

Migraine

Episodic Migraine

Treatments

Drug: CGRP antibody or gepant

Study type

Observational

Funder types

Other

Identifiers

NCT07159750

EOM(AG)008/2024(6234)

Details and patient eligibility

About

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Full description

It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) will be started and baseline assessment will be conducted. There will be visits every 6 months to assess effectiveness, side-effects, PROMs, and elegibility to continue with the study drug. The observation of patients will last 2 years.

Enrollment

700 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Migraine diagnosis according to ICHD-III.
Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
Signature of informed consent.

Exclusion criteria

Presence of headache different from migraine.
Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.